Evidence map›Paper›PMID 28525404›Full record

ReviewCurrent opinion in pediatrics2017

Growth hormone treatment for growth hormone deficiency and idiopathic short stature: new guidelines shaped by the presence and absence of evidence.

Adda Grimberg, David B Allen

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 2 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Growth hormone therapy for people with thalassaemia.The Cochrane database of systematic reviews · 2020
    Pooled it
  3. Article
  4. Barriers to growth hormone access in pediatric patients at an academic medical center.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026
    Article
  5. The Metacarpophalangeal Pattern Profile: An Old Method With New Insights Into the Evaluation of Short Stature.American journal of human biology : the official journal of the Human Biology Council · 2026
    Article
  6. Article
  7. Observational
  8. Correlates of youth involvement in decision making about growth hormone treatment.Families, systems & health : the journal of collaborative family healthcare · 2025
    Article
  9. Review
  10. Review
  11. Review
  12. Observational
  13. Growth Hormone Treatment for Non-GHD Disorders: Excitement Tempered by Biology.The Journal of clinical endocrinology and metabolism · 2024
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Adda GrimbergaDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania bDivision of Endocrinology and Diabetes, The Children's Hospital of Philadelphia cLeonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania dDepartment of Pediatrics, University of Wisconsin School of Medicine and Public Health eDivision of Endocrinology and Diabetes, American Family Children's Hospital, Madison, Wisconsin, USA.
David B Allen
University of Pennsylvania · USUniversity of Wisconsin–Madison · US

Funding

Overcoming Disparities in Growth EvaluationsR01HD057037 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI GRIMBERG, ADDA · 2009 to 2012
$2.1M
NICHD NIH HHS R01 HD057037
6 · The paper itself

Abstract

purpose of reviewThe Pediatric Endocrine Society recently published new guidelines for the use of human growth hormone (hGH) and human insulin-like growth factor-I (hIGF-I) treatment for growth hormone deficiency, idiopathic short stature, and primary IGF-I deficiency in children and adolescents. This review places the new guidelines in historical contexts of the life cycle of hGH and the evolution of US health care, and highlights their future implications. RECENT

findingsThe new hGH guidelines, the first to be created by the Grading of Recommendations Assessment, Development and Evaluation approach, are more conservative than their predecessors. They follow an extended period of hGH therapeutic expansion at a time when US health care is pivoting toward value-based practice. There are strong supporting evidence and general agreement regarding the restoration of hormonal normalcy in children with severe deficiency of growth hormone or hIGF-I. More complex are issues related to hGH treatment to increase growth rates and heights of otherwise healthy short children with either idiopathic short stature or 'partial' isolated idiopathic growth hormone deficiency. SUMMARY: The guidelines-developing process revealed fundamental questions about hGH treatment that still need evidence-based answers. Unless and until such research is performed, a more restrained hGH-prescribing approach is appropriate.

Indexed as

AdolescentChildDwarfism, PituitaryGrowth DisordersHearing Loss, SensorineuralHuman Growth HormoneHumansInsulin-Like Growth Factor IPractice Guidelines as TopicUnited StatesHuman Growth HormoneInsulin-Like Growth Factor I

Identifiers

PMID28525404
PMCPMC5565215
OpenAlexW2615372168

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.